November 18, 9:32 a.m. EST – Dr. Christie Ballantyne, Baylor Coll Med, Houston, TX, will deliver an oral presentation titled, “RNA Interference Targeting Apolipoprotein C-III Results in Deep and Prolonged Reductions in Plasma Triglycerides”

November 18, 9:38 a.m. EST – Dr. Gerald Watts, Univ of Western Australia, Royal Perth Hosp, Perth, Australia, will deliver an oral presentation titled, “RNA Interference Targeting Hepatic Angiopoietin-Like Protein 3 Results in Prolonged Reductions in Plasma Triglycerides and LDL-C in Human Subjects”

Dose Response with the RNA Interference Therapy JNJ-3989 Combined with Nucleos(t)ide Analogue Treatment in Expanded Cohorts of Patients with Chronic Hepatitis B

• Publication Number: 0696
• Session: Hepatitis B - Therapeutics: New Agents
• Session Date and Time: November 8, 2019 from 8:00 AM to 5:30 PM EST
• Location: Hynes Convention Center, Hall B
• Authors: Edward Gane, et al.

FIRST CLINICAL EXPERIENCE WITH RNA INTERFERENCE [RNAi]-BASED TRIPLE COMBINATION THERAPY IN CHRONIC HEPATITIS B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) AND A NUCLEOS(T)IDE ANALOGUE (NA)

• Publication Number: LP4
• Session: Late-Breaking Poster Session
• Session Date and Time: November 11, 2019 from 8:00 AM to 5:30 PM EST
• Location: Hynes Convention Center, Hall B
• Authors: Man-Fung Yuen, et al.

Erik Bush, Ph.D., Arrowhead’s vice president of extra-hepatic targeting, will deliver a poster presentation titled, “Therapeutic Inhibition of ENaC With a Lung-Targeted RNAi Molecule Delivery Platform Preserves Normal Mucus Clearance in a Mucostatic Sheep Model of Cystic Fibrosis”

James Hamilton, M.D., Arrowhead’s vice president of clinical development, will deliver an oral presentation titled, “The emerging safety and activity of siRNA drugs using the TRIMTM platform”

Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will participate in a fireside chat presentation with Keay Nakae, CFA, Chardan senior research analyst

Vince Anzalone, CFA, Arrowhead’s vice president of investor relations, will participate in a fireside chat presentation with Elemer Piros, Ph.D., Cantor Fitzgerald biotechnology equity research analyst

Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, will deliver a keynote presentation titled, “Treating hypertriglyceridemic states with RNA interference – emergence of an exciting new modality to treat cardiovascular diseases”